To Homepage

Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease

Autoren: Gansevoort R, van Gastel M, Chapman A, Blais J, Czerwiec F, Higashihara E, Lee J, Ouyang J, Perrone R, Stade K, Torres V, and Devuyst O
Source: https://doi.org/10.1016/j.kint.2018.11.044
Indication: Nephrology
Product: Copeptin

In the TEMPO 3:4 Trial, treatment with tolvaptan, a vasopressin V2 receptor antagonist, slowed the increase in total kidney volume and decline in estimated glomerular filtration rate (eGFR) in autosomal dominant polycystic kidney disease (ADPKD).
https://www.kidney-international.org/article/S0085-2538(19)30041-9/abstract >

Not all products are CE marked or have 510(k) clearance for sale in the U.S. Availability of products in each country depends on local regulatory marketing authorization status.